Looks like Canaccord is the designated analyst to make the official announcement of the start of biotech pps reversal, buying in by hedgies, and the beginning of a new pumping cycle.
Hedgies don't seem to be done driving biotech down. They really want to buy back dirt cheap before they drive SP up again by ASCO. These people should be locked up with Madoff. Thrown in Steve Cohen there, too, and the other big fishes swimming in dark pools.
I think NVAX has good vaccine technology, but just like many biotechs, it is the market cap that makes it tricky to decide on how good a buy most of these biotechs are. What was that Eu vaccine company that got bought a few years back by JNJ? Crucell! Amazing how I was having a hard time recalling, then just pulled it out from deep recesses of my cluttered brain by the time I typed the question mark. I don't know how much Crucell was bought for.
Make the bleeding stop! My biotech portfolio is more leaky than wet AMD! I'm getting retinal detachment from looking at the falling stock prices! I already had to sell some of my LPTN.
Any good stock for hemophilia? I think SGMO will own hemophilia many years from now with their gene editing technology, but I believe it is overpriced at this time. For now the X-factors will have to do.
I believe we'll get more clinical data from the other partnered drugs this year. If Kadcyla sales don't show signs of slowing down, I'll say we might get back to 2013 highs at least.
Btechs moving up. For real, or another head fake? I believe, there's usually a head fake after AACR, followed by profit taking again before the ASCO rise.
If you're late stage, do you really care about temporary blindness, or even partial blindness for that matter? Should the trials focus perhaps on advance stage patients with few options?
Are there no folate eye drops that they could use to saturate the eye folate receptors before they administer 853? They probably have thought about that.
Will cancer company updates stem the biotech bleeding? I'll be delighted if the cancer stocks at least stay in the green come Monday.
Sunday, April 6:
• Abstract #667 “IMGN853, a folate receptor (FR) α-targeting antibody-drug conjugate (ADC), is highly effective against xenograft models with clinically relevant levels of receptor expression” (1:00-5:00pm PT, Poster Section 28, Poster Board Number 24)
Monday, April 7:
• Abstract #1618 “New peptide-linked anilino-maytansinoid antibody-drug conjugates (ADCs) for the treatment of cancer” (8:00am-12:00pm PT, Poster Section 27, Poster Board Number 1)
• Abstract #2644 “Antibody-drug conjugates (ADCs) with a novel DNA-alkylating agent, DGN462, are highly potent in vitro and in vivo against human cancer models” (1:00-5:00pm PT, Poster Section 31, Poster Board Number 5)
Tuesday, April 8:
• Abstract #4513 “IMGN289, an EGFR-targeting antibody-drug conjugate, is effective against tumor cells that are resistant to EGFR tyrosine kinase inhibitors” (1:00-5:00pm PT, Poster Section 29, Poster Board Number 23)
• Abstract #4641 “Development of modified dosing approaches to achieve specific pharmacokinetic (PK) objectives in the first-in-human phase I clinical trial of IMGN853, a folate receptor α-targeting antibody drug conjugate” (1:00-5:00pm PT, Poster Section 35, Poster Board Number 35)
Combination of man factors. The GILD issue, Crimea, EXEL bad news, and today the HALO bad news. All are shaking biotech longs, and this prolonged pain in the sector is self-propagating because of margin calls. If biotech does not recover on Monday with buyout or other good news, I may have to sell again. I'm afraid manipulators will wait until ASCO abstract release to start pushing biotechs up again. The pattern is not entirely new for this time of year. It just seems much longer this time.
Bad thing is I just added to my IMGN shares when it dipped to 14.30. I may have to resell at a loss.
I buried my money in my backyard when I buried my mother-in-law!
Wait! That's not right! I threw my money overboard in the ocean one dark stormy night. Boy, was she heavy!
Very interesting since most of my biotechs got slammed really hard with rampaging Putin and the Dear Gilead letter. There's something going on under the turbulent biotech waters. Or maybe it's just the missing Malaysian plane.
The pig got fattened on margin, and is now losing all that extra fat. I haven't sold my SGEN since I don't need to, but getting punished on GILD and EXEL. It's easy to get reckless once you have more play money around. I promise I'll play safer next time, hawk. Oddly enough, who would have thought GILD is a reckless play with the S100 price targets that analyst are throwing around.
You know biotechs are being punished when HALO reports a product approval and it still finishes in the red!
Buying opportunity indeed if you have money to spare. With biotech being crashed for more than 2 weeks now, my biotech portfolio, which has many small caps, is down almost 40% for the year. Margin calls have been driving my selling and most probably others as well. Manipulators seem to have no plans soon of letting up.
I've been buying more calls, and some stocks. Reasonably price $3 hits for June. Too soon perhaps.
I disagree, Left-e. I actually enjoy the back and forth discussions. Let's call it intelligent discussions instead of arguments. This is one way we develop intelligent investing decisions. For all you know, you might end up saving some Ohr investors from complete ruin, at the same time join us in LPTN investing. That's why I like Feuerstein even though he's been wrong many times. He at least makes us aware of the bearish points. Other than AF only has good things to say about LPTN.
I agree though about your statement about Elman's 1 responder. I can't really say that he is an unbiased expert.
So if there is not much BBB to speak of when a drug is administered to the eye, why don't drug developers just take that route, instead of struggling to find ways to overcome the BBB for IV drugs for neuro disorders?